Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. It has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-357-2333
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$150,000.00
Profitability
Miscellaneous
Employees22
Next Earnings Date5/10/2019 (Estimated)
OptionableOptionable
Pulmatrix (NASDAQ:PULM) Frequently Asked Questions
What is Pulmatrix's stock symbol?
Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."
When did Pulmatrix's stock split? How did Pulmatrix's stock split work?
Pulmatrix shares reverse split on the morning of Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.
How were Pulmatrix's earnings last quarter?
Pulmatrix Inc (NASDAQ:PULM) released its quarterly earnings data on Tuesday, February, 19th. The biotechnology company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.20) by $0.92. View Pulmatrix's Earnings History.
When is Pulmatrix's next earnings date?
What is the consensus analysts' recommendation for Pulmatrix?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pulmatrix.
Has Pulmatrix been receiving favorable news coverage?
Media stories about PULM stock have trended neutral this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pulmatrix earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the company's share price in the next several days.
Who are some of Pulmatrix's key competitors?
Some companies that are related to Pulmatrix include Leap Therapeutics (LPTX), Helix Biopharma (HBPCF), Novus Therapeutics (NVUS), Novan (NOVN), Aptevo Therapeutics (APVO), Conatus Pharmaceuticals (CNAT), Celsion (CLSN), AzurRx BioPharma (AZRX), Moleculin Biotech (MBRX), ProPhase Labs (PRPH), ContraFect (CFRX), Oncomed Pharmaceuticals (OMED), Advaxis (ADXS), Oncolytics Biotech (ONCY) and Addex Therapeutics (ADDXF).
What other stocks do shareholders of Pulmatrix own?
Who are Pulmatrix's key executives?
Pulmatrix's management team includes the folowing people:
- Dr. Robert W. Clarke, CEO, Pres & Director (Age 50)
- Mr. William E. Duke Jr., CFO, Treasurer & Sec. (Age 47)
- Dr. James M. Roach, Consultant (Age 59)
- Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 70)
- Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 58)
How do I buy shares of Pulmatrix?
Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pulmatrix's stock price today?
One share of PULM stock can currently be purchased for approximately $1.35.
How big of a company is Pulmatrix?
Pulmatrix has a market capitalization of $10.84 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-20,560,000.00 in net income (profit) each year or ($4.98) on an earnings per share basis. Pulmatrix employs 22 workers across the globe.
What is Pulmatrix's official website?
How can I contact Pulmatrix?
Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]
MarketBeat Community Rating for Pulmatrix (NASDAQ PULM)
MarketBeat's community ratings are surveys of what our community members think about Pulmatrix and other stocks. Vote "Outperform" if you believe PULM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PULM will underperform the S&P 500 over the long term. You may vote once every thirty days.
